Play Earnings CallPlay Earnings Call
Alkermes plc (ALKS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST
Company Participants
Richard F. Pops – Chairman & CEO
Conference Call Participants
Jessica Fye – JPMorgan Chase & Co, Research Division
Presentation
Jessica Fye
JPMorgan Chase & Co, Research Division
Great. Welcome, everyone. My name is Jess Fye. I’m a biotech analyst at JPMorgan, and we’re continuing the 44th Annual Healthcare Conference today with Alkermes. We’re going to hear a presentation from the management team, and then we’re going to go into some Q&A.
Because of JPMorgan’s involvement with the pending transaction, we’re not going to take any Q&A related to the pending deal, and I’m not going to be discussing that.
So with that out of the way, let me turn it over to Alkermes, CEO, Richard Pops.
Richard F. Pops
Chairman & CEO
Good morning. Thank you, Jess. Hi, everybody. I’m actually really excited to get to this presentation today in the new year, tell you about Alkermes in 2026, where we stand today and how the accomplishments in 2025, set us up for what we can now see clearly as our next potential phase of growth.
So with that said, I’m going to make forward-looking statements today, as I always do. And it’s described in this slide and this is a business obviously characterized by risk. And we try to go out of our way to describe them in our SEC filings and ask you to take a look at those for a more complete description of them.
So with that said, let’s make forward-looking statements. Let’s — coming into 2026, we’ve built a very strong foundation for growth and value creation for both the near term and the long term. We are a profitable neuroscience company with a late-stage candidate and leadership in an exciting new
